<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0001663'>Ventricular fibrillation</z:hpo> occurs commonly after aortic crossclamping in patients undergoing cardiac surgery </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001663'>Ventricular fibrillation</z:hpo> increases myocardial oxygen consumption, and defibrillation may harm the myocardium </plain></SENT>
<SENT sid="2" pm="."><plain>Thus, a pharmacologic approach to decreasing the incidence of <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> or the number of shocks required may be beneficial </plain></SENT>
<SENT sid="3" pm="."><plain>The goal of this study was to evaluate whether <z:chebi fb="0" ids="2663">amiodarone</z:chebi> or <z:chebi fb="0" ids="6456">lidocaine</z:chebi> was superior to placebo for the prevention of <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> after aortic crossclamping in patients undergoing a variety of cardiac surgical procedures </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Patients undergoing cardiac surgery requiring aortic crossclamping were randomized to receive <z:chebi fb="0" ids="6456">lidocaine</z:chebi> 1.5 mg/kg, <z:chebi fb="0" ids="2663">amiodarone</z:chebi> 300 mg, or placebo before aortic crossclamp removal The primary outcomes were the incidence of <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> and the number of shocks required to terminate <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: A total of 342 patients completed the trial </plain></SENT>
<SENT sid="6" pm="."><plain>On multivariate analysis, there was no difference in the incidence of <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> among treatment groups </plain></SENT>
<SENT sid="7" pm="."><plain>The number of required shocks was categorized as 0, 1 to 3, and greater than 3 </plain></SENT>
<SENT sid="8" pm="."><plain>On multivariate analysis, patients receiving <z:chebi fb="0" ids="2663">amiodarone</z:chebi> required fewer shocks to terminate <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (odds ratio, 0.51; 95% confidence interval, 0.31-0.83; P = .008 vs placebo) </plain></SENT>
<SENT sid="9" pm="."><plain>There was no difference between <z:chebi fb="0" ids="6456">lidocaine</z:chebi> and placebo in the number of required shocks (odds ratio, 0.86; 95% confidence interval, 0.52-1.41; P = .541) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In patients undergoing a variety of cardiac surgical procedures, neither <z:chebi fb="0" ids="2663">amiodarone</z:chebi> nor <z:chebi fb="0" ids="6456">lidocaine</z:chebi> reduced the incidence of <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="2663">Amiodarone</z:chebi> decreased the number of shocks required to terminate <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> </plain></SENT>
</text></document>